

Dealdoc**Collaboration and licensing agreement for NPT200-11**

UCB
Neuropore Therapies

Jan 16 2015

Collaboration and licensing agreement for NPT200-11

Companies:	UCB Neuropore Therapies
Announcement date:	Jan 16 2015
Amendment date:	Sep 13 2016
Deal value, US\$m:	480 : sum of upfront and milestone payments

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Jan 16 2015
Amendment date:	Sep 13 2016
Start date:	Dec 31 2014
Industry sectors:	Bigpharma Biotech Pharmaceutical
Compound name:	NPT200-11, UCB0599
Exclusivity:	Exclusive
Asset type:	Compound
Therapy areas:	Central Nervous System Central Nervous System » Parkinson's disease
Deal components:	Collaborative R&D Licensing
Stages of development:	Phase I
Geographic focus:	Worldwide

Financials

Deal value, US\$m:	480 : sum of upfront and milestone payments
Upfront, US\$m:	20 : initial upfront payment 460 : development, regulatory and sales-based milestones payments
Milestones, US\$m:	5 : progression milestone on September 2016 5 : award as a result of initiated a multicenter clinical trial
Royalty rates, %:	n/d : royalties on net sales

Termsheet

May 2021

Neuropore Therapies has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson's Disease. UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration and License Agreement entered into between Neuropore Therapies and UCB Biopharma on December 31, 2014.

Neuropore will receive a \$20 million (USD) milestone payment as a result of the continued clinical progress of UCB0599.

Neuropore Therapies granted UCB an exclusive world-wide license to research, develop and commercialize alpha-synuclein targeting molecules in all indications.

As a result of this latest milestone achievement, Neuropore Therapies has cumulatively received \$63 million of the potential \$460 million in total milestones available through its collaboration with UCB.

May 2019

Neuropore Therapies announced that partner UCB initiated a multicenter clinical trial in Parkinson's disease patients with UCB0599 in the United States of America.

UCB0599, an alpha-synuclein misfolding inhibitor, is a therapeutic candidate arising from the Neuropore-UCB collaboration.

Neuropore will receive a \$5 million (USD) award as a result of achieving this milestone.

September 2016

Neuropore Therapies announced have successfully achieved a key program milestone in their collaboration with UCB.

After successful completion of a randomized, double-blind, placebo controlled single ascending dose clinical study and additional non-clinical studies, UCB has awarded NPTTM a progression milestone of \$5 million.

January 2015

Neuropore Therapies and UCB have entered into a world-wide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson's disease and related disorders.

This includes NPT200-11, Neuropore's novel small molecule that targets pathogenic alpha-synuclein which is currently in preclinical development and is expected to enter clinical Phase 1 in 2015.

UCB will receive the world-wide exclusive license to develop and commercialize NPT200-11 in all indications. UCB and Neuropore will work together to complete non-clinical studies, and a first Phase 1 study to be initiated in 2015.

UCB will lead all further clinical development, regulatory activities and commercialization.

Neuropore will receive an initial upfront payment of US\$20 million and is entitled to potential development, regulatory and sales-based milestones payments, of up to a potential total of US\$460 million, in addition to royalties on net sales.

Press Release

May 2021

Neuropore Therapies Receives \$20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB

May 17, 2021 12:01 UTC

SAN DIEGO--(BUSINESS WIRE)--Neuropore Therapies, Inc. announced today that it has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson's Disease. UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration and License Agreement entered into between Neuropore Therapies, Inc and UCB Biopharma SRL on December 31, 2014. Neuropore will receive a \$20 million (USD) milestone payment as a result of the continued clinical progress of UCB0599.

"We are pleased to see UCB0599 progress into a proof of concept study in patients with early Parkinson's disease. We believe that inhibition of alpha-synuclein misfolding and oligomerization with an orally active, brain penetrating, small molecule represents a promising therapeutic approach. We are excited that UCB0599 is being given this opportunity to demonstrate potential therapeutic benefit in Parkinson's disease patients," stated Doug Bonhaus, President and CEO of Neuropore Therapies.

As announced in January 2015, Neuropore Therapies granted UCB an exclusive world-wide license to research, develop and commercialize alpha-synuclein targeting molecules in all indications. As a result of this latest milestone achievement, Neuropore Therapies has cumulatively received \$63 million (USD) of the potential \$460 million (USD) in total milestones available through its collaboration with UCB.

About Parkinson's disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. There are an estimated seven to ten million patients with PD worldwide. The age of onset is approximately 60 years. Current treatments for PD are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease progresses and dopaminergic

neurons continue to be lost, these drugs eventually become less effective at treating the symptoms.

About UCB0599

UCB0599 is an orally bioavailable, brain barrier penetrant small molecule that prevents the oligomerization of alpha-synuclein. Alpha-synuclein oligomerization and aggregation is implicated in Parkinson's disease and other degenerative diseases. By inhibiting misfolding and oligomerization of alpha-synuclein, it is believed that the progression of Parkinson's disease can be slowed or halted. UCB0599 belongs to a series of molecules discovered by Neuropore, which were licensed to UCB in 2014. For more information on this clinical trial with UCB0599 visit <https://www.clinicaltrials.gov/>.

About Neuropore Therapies, Inc.

Neuropore Therapies Inc. is a San Diego, California based biopharmaceutical company developing novel disease modifying small molecule therapeutics for the treatment of neurodegenerative disorders by targeting underlying mechanisms related to protein pathology and neuroinflammation. For more information visit www.neuropore.com.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7,600 people in approximately 40 countries, the company generated revenue of €4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

May 2019

UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson's Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration

May 28, 2019 12:01 UTC SAN DIEGO--(BUSINESS WIRE)-- Neuropore Therapies, Inc. announced today that partner UCB initiated a multicenter clinical trial in Parkinson's disease patients with UCB0599 in the United States of America. UCB0599, an alpha-synuclein misfolding inhibitor, is a therapeutic candidate arising from the Neuropore-UCB collaboration. Neuropore will receive a \$5 million (USD) award as a result of achieving this milestone.

"We are pleased to reach the milestone of advancing into Parkinson's patients for the first time with UCB0599, a therapeutic candidate arising from our collaboration with UCB. We believe that inhibition of alpha-synuclein misfolding and oligomerization with an orally active, brain penetrant, small molecule represents a potential advantage over antibody therapeutics that are currently in development," stated Errol De Souza, President and CEO of Neuropore Therapies.

As announced in January 2015, Neuropore Therapies granted UCB a world-wide license to develop and commercialize alpha-synuclein targeting molecules in all indications. As a result of the milestone achieved with UCB0599, Neuropore will have cumulatively received \$43 million of the potential \$460 million in total milestones through its collaboration with UCB.

About Parkinson's disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. There are an estimated seven to ten million patients with PD worldwide. The age of onset is approximately 60 years. Current treatments for PD are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease progresses and dopaminergic neurons continue to be lost, these drugs eventually become less effective at treating the symptoms.

About UCB0599

UCB0599 is an orally bioavailable, brain barrier penetrant small molecule that prevents the oligomerization of alpha-synuclein. Alpha-synuclein oligomerization and aggregation is implicated in Parkinson's disease and other degenerative diseases. By inhibiting misfolding and oligomerization of alpha-synuclein, it is believed that the progression of Parkinson's disease can be slowed or halted. UCB0599 belongs to a series of molecules discovered by Neuropore, which were licensed to UCB in 2014.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology or neurology. With around 7,500 people, operating in 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUS

About Neuropore Therapies, Inc.

Neuropore Therapies Inc. is a San Diego, California based biopharmaceutical company developing novel disease modifying small molecule therapeutics for the treatment of neurodegenerative disorders. Neuropore's therapeutic candidates block the neurotoxic oligomeric aggregates of misfolded proteins which are the primary drivers of disease pathology by preventing the induction of damaging neuroinflammation mechanisms common to many neurodegenerative disorders. By targeting the underlying mechanisms by which neuroinflammation drives the cycle of protein pathology and neurodegeneration, Neuropore's therapeutic candidates could have broad applications in slowing disease progression and improving symptoms across a wide range of neuro- inflammatory / neuro-degenerative disorders.

Neuropore possesses a pipeline with two therapeutic candidates in clinical development, UCB0599 and NPT520-34. In addition, Neuropore is developing several other small molecule programs that are in lead optimization and/or preclinical development.

For more information visit www.neuropore.com

September 2016

September 13, 2016 08:07 AM: SAN DIEGO--(BUSINESS WIRE)--Neuropore Therapies, Inc. announced today that they have successfully achieved a key program milestone in their collaboration with UCB. After successful completion of a randomized, double-blind, placebo controlled single ascending dose clinical study and additional non-clinical studies, UCB has awarded NPTTM a progression milestone of \$5 million.

"We are very pleased with UCB's decision to proceed with the development of this novel therapeutic candidate that initially arose from Neuropore's drug-discovery platform. This is an important milestone for Neuropore and reflects UCB's continued commitment to a promising therapeutic opportunity for the treatment of Parkinson's disease," commented Doug Bonhaus, Ph.D., Neuropore's COO.

About Parkinson's disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. There are an estimated seven to ten million patients with PD worldwide. Current treatments for PD are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease progresses and dopaminergic neurons continue to be lost, these drugs eventually become less effective at treating the symptoms. Currently there are no approved disease modifying treatments for PD.

About Neuropore Therapies, Inc. (NPTTM)

Neuropore Therapies is a pharmaceutical company committed to the discovery and development of disease-modifying treatments for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease.

Our approach is based on the fundamental concept that the pathological accumulation of misfolded and aggregated neurotoxic proteins is the underlying basis of these disorders. Our therapeutic candidates directly target these proteins and restore cellular autophagy mechanisms to degrade and dispose of these neurotoxic proteins.

The NPTTM Discovery and Development Platform utilizes structure-based drug design, dynamic molecular modeling, and proprietary in vitro and in vivo models to discover and develop novel small molecule drug candidates that facilitate the cellular clearance of toxic misfolded proteins and provide therapeutic benefit to patients with neurodegenerative disorders. NPTTM200-11 is the most advanced product arising from this platform.

In 2014 Neuropore Therapies entered into a collaboration and world-wide exclusive license agreement with UCB.

For more information visit www.neuropore.com.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7700 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

January 2015

Neuropore and UCB enter into world-wide collaboration and agreement

Companies collaborate in the development of a small molecule disease modifying treatment option for people living with Parkinson's disease

Clinical Phase 1 study scheduled to start in 2015

San Diego, CA and Brussels (Belgium) – 16 January 2015 7:00am (CET) – Neuropore Therapies Inc. and UCB announced today that they have entered into a world-wide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson's disease and related disorders. This includes NPT200-11, Neuropore's novel small molecule that targets pathogenic alpha-synuclein

which is currently in preclinical development and is expected to enter clinical Phase 1 in 2015.

"Parkinson's disease is a debilitating neurodegenerative disorder that results in disruption of normal movement and motor function, as well as cognitive and other life-altering symptoms", said Ismail Kola, President UCB New Medicines™. "People living with Parkinson's disease need better treatment options, especially as there is currently no approved treatment that addresses a fundamental pathological mechanism in Parkinson's disease. With Neuropore's NPT200-11, we have the opportunity to develop a disease modifying treatment option for patients with Parkinson's disease and other synucleinopathies."

"We are excited to partner with UCB, a global leader in developing drugs to treat neurological diseases," said Dieter Meier, Neuropore's CEO. "By working together we wish to accelerate the development of new treatments that can halt or slow the progression of Parkinson's disease and other neurodegenerative diseases for patients who suffer from such debilitating conditions. UCB's commitment and expertise in this field offers the best opportunity to collaboratively develop orally available small molecules to treat diseases that affect large patient populations and possibly certain orphan diseases. We anticipate that this partnership will contribute to Neuropore's further growth to become a leader in discovering and developing innovative nervous system therapies."

Under the terms of the agreement, UCB will receive the world-wide exclusive license to develop and commercialize NPT200-11 in all indications. UCB and Neuropore will work together to complete non-clinical studies, and a first Phase 1 study to be initiated in 2015. UCB will lead all further clinical development, regulatory activities and commercialization. Neuropore will receive an initial upfront payment of US\$20 million and is entitled to potential development, regulatory and sales-based milestones payments, of up to a potential total of US\$460 million, in addition to royalties on net sales.

About Parkinson's disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. There are an estimated seven to ten million patients with PD worldwide. Current treatments for PD are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease progresses and dopaminergic neurons continue to be lost, these drugs eventually become less effective at treating the symptoms.

About NPT 200-11

By stabilizing conformations of alpha-synuclein that are then incapable of assembling into toxic pore-like oligomers in cell membranes, NPT200-11, blocks the pathological protein misfolding, aggregation and deposition that contribute to synaptic dysfunction and cell death in PD and related disorders. NPT200-11 is orally bioavailable, has promising drug-like properties and, has shown robust beneficial actions on multiple endpoints in animal models.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

About Neuropore Therapies Inc Neuropore Therapies is developing novel small molecule therapeutics to treat and slow the progression of neurodegenerative disorders such as Alzheimer's and Parkinson's disease. The approach being taken by Neuropore is to target an underlying pathological process common to these disorders – the accumulation of toxic oligomeric aggregates of misfolded neuronal proteins in cell membranes. By preventing the formation of these toxic aggregates synaptic function may be restored and neurodegenerative processes slowed.

Neuropore Therapies uses structure-based drug design and dynamic molecular modeling to identify key target regions on proteins that are important for the formation of toxic protein aggregates. Candidate compounds targeting these regions are then synthesized and evaluated in cell-free and cell-based assays systems. Promising compounds are then evaluated in various disease-related animal models. For more information visit www.neuropore.com

Filing Data

Not available.

Contract

Not available.